Article Data

  • Views 412
  • Dowloads 101

Original Research

Open Access

Confluence analysis of multiple omics on platinum resistance of ovarian cancer

  • Xinhong Ye1,*,

1Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

DOI: 10.12892/ejgo2659.2015 Vol.36,Issue 5,October 2015 pp.514-519

Published: 10 October 2015

*Corresponding Author(s): Xinhong Ye E-mail: yexinred@163.com

Abstract

Objective: The study aimed to provide novel insight into the mechanism of platinum resistance of ovarian cancer. Materials and Methods: RNA-seq data ERP000710 were obtained from Gene Expression Omnibus database, including specimens from six platinum sensitive samples and six platinum tolerance samples. The author analyzed the data of the 12 samples as a whole because of the low flux sequencing. Single nucleotide polymorphisms (SNPs) were identified between platinum-sensitive and platinum-tolerant samples using VARSCAN, followed by functional prediction of the SNPs. After processed by Btrim software, the data were subjected to Cuffdiff for the identification of differentially expressed genes (DEGs), followed by function and pathway enrichment analysis. In addition, VARSCAN software was used to detect the specific mutations in platinum tolerance samples, combined with functional prediction of mutations. Results: The author obtained 38 new SNPs after excluding 22 SNP from dbSNP database and 1000 Genomes Project and found ESRP1, LDHA, DDX5, and HEXA were associated with platinum resistance of ovarian cancer. Totally, 290 upregulated and 157 downregulated genes were selected. Biological processes such as immune response, inflammatory response, and response to wounding and pathways such as cell adhesion molecules, calcium signaling, and NOD-like receptor signaling pathways were enriched with upregulated genes. Cell-cell signaling, cell morphogenesis, and basal cell carcinoma pathway were related to downregulated genes. Conclusion: Based on high-throughput RNA-seq data and confluence analysis of multiple omics, the author explored the biological mechanisms on platinum tolerance of ovarian cancer, which may provide new ideas and methods for further research.

Keywords

Ovarian cancer; Differentially expressed genes (DEGs); Single nucleotide polymorphisms (SNPs); Function and pathways enrichment.

Cite and Share

Xinhong Ye. Confluence analysis of multiple omics on platinum resistance of ovarian cancer. European Journal of Gynaecological Oncology. 2015. 36(5);514-519.

References

[1] Bray F., Loos A. H., Tognazzo S., La Vecchia C.: “Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 coun-tries, 1953-2000”. Int J Cancer. 2005, 113, 977.

[2] Bankhead C. R., Kehoe S. T., Austoker J.: “Symptoms associated with diagnosis of ovarian cancer: a systematic review”. BJOG, 2005, 112, 857.

[3] Hippisley-Cox J., Coupland C.: “Identifying women with suspected ovarian cancer in primary care: derivation and validation of algo-rithm”. BMJ, 2012, 344, d8009.

[4] Bridda A., Padoan I., Mencarelli R., Frego M.: “Peritoneal mesothe-lioma: a review”. MedGenMed., 2007, 9, 32.

[5] Pearce C. L., Templeman C., Rossing M. A., Lee A., Near A. M., Webb P. M., et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol., 2012, 13, 385.

[6] Chobanian N., Dietrich C.S. 3rd.: “Ovarian cancer”. Surg. Clin. North Am., 2008, 88, 285.

[7] Lister-Sharp D., McDonagh M. S., Khan K. S., Kleijnen J.: “A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian can-cer”. Health Technol Assess., 2000, 4, 1.

[8] Hoskins P. J., Swenerton K. D., Pike J. A., McMurtrie E. M., Lee N.: “ "MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian can-cer”. Gynecol. Oncol., 1996, 63, 345.

[9] Kartalou M., Essigmann J. M.: “Mechanisms of resistance to cis-platin. Mutat.Res., 2001, 478, 23.

[10] Reed E.: “Platinum-DNA adduct, nucleotide excision repair and plat-inum based anti-cancer chemotherapy”. Cancer Treat. Rev., 1998, 24, 331.

[11] Zanotti K. M., Belinson J. L., Kennedy A. W., Webster K. D., Mark-man M.: “Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy”. Gynecol. Oncol., 2000, 79, 211.

[12] Arseneault R., Chien A., Newington J. T., Rappon T., Harris R., Cumming R.C.: “Attenuation of LDHA expression in cancer cells leads to redox-dependent alterations in cytoskeletal structure and cell migration”. Cancer Lett., 2013., 338, 255.

[13] Ng C.K., Cooke S.L., Howe K., Newman S., Xian J., Temple J., et al.: “The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer”. J. Pathol., 2012, 226, 703.

[14] Kong Y.: “Btrim: a fast, lightweight adapter and quality trimming program for next-generation sequencing technologies”. Genomics, 2011, 98, 152.

[15] Kim D., Pertea G., Trapnell C., Pimentel H., Kelley R., Salzberg S. L.: “TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions”. Genome Biol., 2013, 14, R36.

[16] Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., et al.: “The sequence alignment/map format and SAMtools”. Bioinformatics.

[17] Koboldt D. C., Chen K., Wylie T., Larson D. E., McLellan M. D., Mardis E. R., et al.: “VarScan: variant detection in massively paral-lel sequencing of individual and pooled samples”. Bioinformatics, 2009, 25, 2283.

[18] Hastings K. T., Cresswell P.: “Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase”. Antioxid. Redox Signal., 2011, 15, 657.

[19] Trapnell C., Hendrickson D. G., Sauvageau M., Goff L., Rinn J. L., Pachter L.: “Differential analysis of gene regulation at transcript res-olution with RNA-seq”. Nat. Biotechnol., 2012, 31, 46.

[20] Ashburner M., Ball C. A., Blake J. A., Botstein D., Butler H., Cherry J. M., et al.: “Gene Ontology: tool for the unification of biology”. Nat. Genet., 2000, 25, 25.

[21] Alvord G., Roayaei J., Stephens R., Baseler M. W., Lane H. C., Lem-picki R.A.: “The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists”. Genome Biol., 2007, 8, R183.

[22] Kanehisa M., Goto S.: “KEGG: kyoto encyclopedia of genes and genomes”. Nucleic Acids Res., 2000, 28, 27.

[23] Westbrook K., Stearns V.: “Pharmacogenomics of breast cancer ther-apy: an update”. Pharmacol. Ther., 2013, 139, 1.

[24] Wang Z., Gerstein M., Snyder M.: “RNA-Seq: a revolutionary tool for transcriptomics”. Nat. Rev. Genet., 2009, 10, 57.

[25] Raz T., Kapranov P., Lipson D., Letovsky S., Milos P. M., Thomp-son J.F.: “Protocol dependence of sequencing-based gene expression measurements”. PLoS One, 2011, 6, e19287.

[26] Cancer Genome Atlas Research Network: “Comprehensive genomic characterization defines human glioblastoma genes and core path-ways”. Nature. 2008, 455, 1061.

[27] Rosell R., Lord R. V. N., Taron M., Reguart N.: “DNA repair and cisplatin resistance in non-small-cell lung cancer”. Lung Cancer, 2002, 38, 217.

[28] Glisovic T., Bachorik J. L., Yong J., Dreyfuss G.: “RNA-binding pro-teins and post-transcriptional gene regulation”. FEBS Lett., 2008,2009, 25(16):2078. 582, 1977.

[29] Yae T., Tsuchihashi K., Ishimoto T., Motohara T., Yoshikawa M., Yoshida G. J., et al.: “Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell”. Nat Commun., 2012, 3, 883.

[30] Sheng S. L., Liu J. J., Dai Y. H., Sun X. G., Xiong X. P., Huang G.: “Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma”. FEBS J., 2012, 279, 3898.

[31] Mazurek A., Luo W., Krasnitz A., Hicks J., Powers R. S., Stillman B.: “DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells”. Cancer Discov., 2012, 2, 812.

[32] Wang D., Huang J., Hu Z.: “RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells”. Mol. Cell Proteomics, 2012, 11, M111.011932.

[33] Clark E. L., Hadjimichael C., Temperley R., Barnard A., Fuller-Pace F. V., Robson C.N.: “p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer”. PLoS One, 2013, 8, e54150.

[34] Han B., Mehra R., Dhanasekaran S. M., Yu J., Menon A., Lonigro R. J., et al.: “A fluorescence in situ hybridization screen for E26 transformation–specific aberrations: identification of DDX5- ETV4 fusion protein in prostate cancer”. Cancer Res., 2008, 68, 7629.

[35] Cohen S., Mosig R., Moshier E., Pereira E., Rahaman J., Prasad- Hayes M., et al.: “Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma”. Gynecol. Oncol., 2014, 134, 591.

[36] Cohen S., Bruchim I., Graiver D., Evron Z., Oron-Karni V., Pas-manik-Chor M., et al.: “Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its tar-get cIAP-2”. J. Mol. Med. (Berl.), 2013, 91, 357.

[37] Li M., Balch C., Montgomery J. S., Jeong M., Chung J., Yan P., et al.: “Integrated analysis of DNA methylation and gene expression re-veals specific signaling pathways associated with platinum resist-ance in ovarian cancer”. BMC Med. Genomics, 2009, 2, 34.

[38] Toriola A. T., Surcel H.M., Calypse A., Grankvist K., Luostarinen T., Lukanova A., et al.: “Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: A prospective nested case–control study”. Eur. J. Cancer, 2010, 46, 2799.

[39] Ashton K. A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al.: “Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endome-trial cancer risk. BMC Cancer, 2010, 10, 382.

[40] Gorp H.V., Kuchmiy A., Hauwermeiren F.V., Lamkanfi M.: “NOD-like receptors interfacing the immune and reproductive systems”. FEBS J., 2014, 281, 4568.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top